Borage oil is the richest plant source of an unusual omega-6 fat the body turns into inflammation-calming compounds. Its strongest support is as an add-on for rheumatoid arthritis joint pain over months; it modestly helps dry, aging skin but does not help eczema. Mild digestive upset is common; contamination by natural plant toxins is the main safety concern. (Full Review)

Protocol

Arthritis dose

1.4–2.8 g GLA daily

~6–11 g oil at 23% GLA, add-on for at least 6 months

Skin / general dose

240–720 mg GLA daily

~1–3 g oil for skin barrier support and general anti-inflammatory aims

Administration

Take with largest meals

Larger arthritis doses split across two or three meals; lower doses once daily

Time to effect

Arthritis symptoms

At least 6 months

Trials required this long to show joint-pain effects

Skin barrier

Several weeks

Skin-barrier changes take several weeks to appear

Tissue saturation

Several weeks to plateau

Tissue fatty-acid levels take several weeks to plateau; not for acute relief

Benefits

Medium: Rheumatoid arthritis symptom relief; skin barrier function in dry and aging skin

Low: Reduced inflammatory and oxidative markers; diabetic peripheral neuropathy

Speculative: Respiratory and asthmatic inflammation; hormonal and premenstrual complaints

Contraindications

Pregnancy or breastfeeding

Liver disease or history of liver injury

Bleeding disorders or surgery within two weeks

Epilepsy, especially on phenothiazines

Cannot verify product is certified free of unsaturated pyrrolizidine alkaloids

Key Interactions

Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin)

Phenothiazine antipsychotics (chlorpromazine, prochlorperazine)

NSAIDs and other anti-inflammatories (ibuprofen, naproxen)

Anticonvulsants

Supplement interactions (additive): fish oil, evening primrose oil, blackcurrant seed oil, vitamin E, Ginkgo biloba, high-dose garlic

Supplement interactions (intended pairing): sesame lignans

Risk & Side Effects

Medium: Gastrointestinal upset

Low: Pyrrolizidine alkaloid contamination; increased bleeding risk

Speculative: Lowered seizure threshold; theoretical pro-inflammatory conversion

Monitoring

Marker	Target	Why
hs-CRP	< 1.0 mg/L	Tracks body-wide inflammation, the main target in arthritis use
ALT	< 25 U/L (men), < 20 U/L (women)	Screens for liver stress relevant to pyrrolizidine alkaloid risk
AST	< 25 U/L	Complements ALT in detecting liver injury
ESR	< 10–15 mm/hr	Secondary inflammation marker tracking arthritis disease activity
Platelet count and basic clotting (INR if on warfarin)	Within normal lab range; INR per target	Surveils the additive bleeding risk with anticoagulants

Cadence: Baseline before starting; for long-term or arthritis-dose use, about 3 months after starting, then every 6–12 months

Qualitative Assessment

Joint pain, morning stiffness, and tenderness or swelling (for arthritis use)
Skin dryness, itch, and softness or barrier comfort (for skin use)
General sense of inflammatory burden, such as recovery and overall comfort
Any new bruising, nosebleeds, or gastrointestinal upset as early safety signals

Borage Oil for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment